{{short description|Global academic network}} {{Use dmy dates|date=August 2019}} {{Multiple issues| {{notability|Companies|date=June 2018}} {{third-party|date=June 2018}} }} {{Research-Project | name = TREAT-NMD | title = Translational Research in Europe - Assessment and Treatment of Neuromuscular diseases | keywords = Neuromuscular diseases, clinical research | fundingAgency = European Commission | frameworkProgramme = Sixth Framework Programme|image = | projectType = Network of Excellence | researchObjective = Improving trial-readiness worldwide, advancing patient diagnosis and care and accelerating pre-clinical research | projectReference = FP6-036825 | coordinator = Institute of Genetic Medicine, Newcastle University | participants = Universities, pharmaceutical companies, patient organisations | website = {{url|www.treat-nmd.org}} }} '''TREAT-NMD''' (Translational Research in Europe, Assessment and Treatment for NeuroMuscular Disorders) is a global academic network that focuses on advancing research in neuromuscular disorders.<ref name="Leary_2017">{{Cite journal |last1=Leary |first1=Rebecca |last2=Oyewole |first2=Anne |last3=Bushby |first3=Katharine |last4=Aartsma-Rus |first4=Annemieke |date=2017-07-06 |title=Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD) | journal=Neuropediatrics |volume=48 |issue=4 |pages=211–220 | pmid = 28683502 |doi=10.1055/s-0037-1604110 |s2cid=19283049 }}</ref> It was established in 2007 with its coordination centre at the Newcastle University.<ref>{{cite journal | first1 = Katharine | last1 = Bushby | first2 = Stephen | last2 = Lynn | first3 = Volker | last3 = Straub <!-- | vauthors = Bushby K, Lynn S, Straub T --> | title = Collaborating to bring new therapies to the patient--the TREAT-NMD model | journal = Acta Myologica | volume = 28 | issue = 1 | pages = 12–5 | date = July 2009 | pmid = 19772190 | pmc = 2859629 }}</ref> As of 2018, the network comprises over a hundred research centres and patient organisations from 54 countries<ref>{{cite web |url=http://www.treat-nmd.eu/about/membership/organizations/ |title=TREAT-NMD Alliance Members – Organizations | work = TREAT Neuromuscular Network |access-date=2018-06-13}}</ref> as well as independent academics and patient representatives.<ref>{{Cite web |url=http://www.treat-nmd.eu/about/membership/individuals/ |title=TREAT-NMD Alliance Members – Individuals | work = TREAT Neuromuscular Network |access-date=2018-06-13}}</ref> The network's aim is to provide infrastructure to accelerating research through supporting collaboration between its members.<ref>{{Cite web |url=http://www.treat-nmd.eu/about/network/about-network/ |title=TREAT-NMD : About the TREAT-NMD network | work = TREAT Neuromuscular Network }}</ref> Its main goals include improving trial-readiness worldwide, advancing patient diagnosis and care and accelerating pre-clinical research.<ref>{{cite journal | first1 = Raffaella | last1 = Willmann | first2 = Markus A. | last2 = Rüegg | first3 = Rebecca J. | last3 = Fairclough | first4 = Kay E | last4 = Davies | first5 = Stefanie | last5 = Possekel | first6 = Thomas | last6 = Meier <!-- | vauthors = Willmann R, Rüegg MA, Fairclough R, Davies KE, Possekel S, Meier T --> |title=T.P.3.03 TREAT-NMD-Activity 7: Accelerate preclinical phase of new therapeutic treatment development |journal=Neuromuscular Disorders |date=October 2008 |volume=18 |issue=9–10 |pages=794 |doi=10.1016/j.nmd.2008.06.242 | s2cid = 54330245 |type=Conference abstract}}</ref><ref>{{cite journal | first1 = Eugenio Maria | last1 = Mercuri | first2 = Anna G | last2 = Mayhew | first3 = Francesco | last3 = Muntoni | first4 = Volker | last4 = Straub | first5 = Gert-Jan | last5 = Van Ommen | first6 = Thomas | last6 = Voit | first7 = Enrico | last7 = Bertini | first8 = Katherine | last8 = Bushby <!-- | vauthors = Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, Voit T, Bertini E, Bushby K --> | title = Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France | journal = Neuromuscular Disorders | volume = 18 | issue = 11 | pages = 894–903 | date = November 2008 | pmid = 18818076 | doi = 10.1016/j.nmd.2008.07.003 |type=Workshop report | doi-access = free }}</ref>
Through patient registries, TREAT-NMD provides genotype–phenotype correlation between genetic mutations and neuromuscular disease burden.<ref name="Thompson_2017">{{cite book | vauthors = Thompson R, Robertson A, Lochmüller H | title = Rare Diseases Epidemiology: Update and Overview | chapter = Natural History, Trial Readiness and Gene Discovery: Advances in Patient Registries for Neuromuscular Disease | series = Advances in Experimental Medicine and Biology | volume = 1031 | pages = 97–124 | date = 2017 | pmid = 29214567 | doi = 10.1007/978-3-319-67144-4_5 | isbn = 978-3-319-67142-0 }}</ref>
==References== {{reflist|30em}}
==Further reading== {{refbegin}} *{{Cite journal |last1=Heslop |first1=Emma |last2=Csimma |first2=Cristina |last3=Straub |first3=Volker |last4=McCall |first4=John |last5=Nagaraju |first5=Kanneboyina |last6=Wagner |first6=Kathryn R. |last7=Caizergues |first7=Didier |last8=Korinthenberg |first8=Rudolf |last9=Flanigan |first9=Kevin M. |date=2015-04-23 |title=The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development |journal=Orphanet Journal of Rare Diseases |volume=10 |issue=1 |pages=49 |doi=10.1186/s13023-015-0258-1 |pmc= 4417237 |pmid=25902795 |doi-access=free }} *{{Cite journal |last1=Bladen |first1=Catherine L. |last2=Rafferty |first2=Karen |last3=Straub |first3=Volker |last4=Monges |first4=Soledad |last5=Moresco |first5=Angélica |last6=Dawkins |first6=Hugh |last7=Roy |first7=Anna |last8=Chamova |first8=Teodora |last9=Guergueltcheva |first9=Velina |date=2013-08-26 |title=The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia |journal=Human Mutation |volume=34 |issue=11 |pages=1449–1457 | pmid = 23913485 |doi=10.1002/humu.22390 |s2cid=38772058 |doi-access=free }} *{{cite journal |last1=Aartsma-Rus |first1=Annemieke |last2=Mercuri |first2=Eugenio |last3=Vroom |first3=Elizabeth |last4=Balabanov |first4=Pavel | title = Meeting report of the "Regulatory Exchange Matters" session at the 5th International TREAT-NMD Conference:: Lessons in communication: How an early dialogue between patients, regulators and academics can further therapy development for neuromuscular disorders Freiburg, Germany, 27-29 November 2017 | journal = Neuromuscular Disorders | volume = 28| issue = 7| pages = 619–623| date = April 2018 | pmid = 29778308 | doi = 10.1016/j.nmd.2018.04.009 |doi-access=free }} {{refend}}
Category:Medical research organizations